PR Newswire Asia's news > Biotechnology

 |   Title only   |   Print    Next page > 
     
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE , Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG , Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered ...
2025-08-19T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. DXVX is taking the lead in business development, with several ...
2025-08-18T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING , Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, ...
2025-08-18T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
Revenue reached approximately RMB950.4 million , with total commercial sales RMB309.8million , representing a significant increase in proportion Research and development expenses was approximately ...
2025-08-18T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea , Aug. 18, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with ...
2025-08-18T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
-  Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor ( GLP-1R ) and GIP receptor ( GIPR ) , resulted in a 44.8% reduction in body weight ...
2025-08-18T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation ...
2025-08-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.